Business Context and Reporting Period
This Form 8-K, dated January 9, 2023, reports that First Light Acquisition Group, Inc. (FLAG) has entered into a definitive Agreement and Plan of Merger with Calidi Biotherapeutics, Inc. (Calidi). The transaction involves a business combination where a subsidiary of FLAG will merge with Calidi, with Calidi surviving as the public entity. The filing details the terms of the merger, related agreements, and conditions to closing.
Key Financial Metrics and Transaction Terms
- Equity Valuation: The aggregate consideration is based on an equity value of $250,000,000 for Calidi, subject to adjustments.
- Net Debt Adjustment: The consideration will be adjusted based on the difference between Calidi's actual "net debt" at closing and a target "net debt" amount.
- Minimum Cash Condition: Closing is conditioned on the combined entity having at least $15,000,000 in cash and cash equivalents (post-redemptions, including PIPE and Sponsor-Assisted Equity proceeds).
- PIPE Investment: FLAG may secure up to $40,000,000 in private investment in public equity (PIPE) between signing and closing.
- Permitted Equity Issuance: Calidi is permitted to raise up to $40,000,000 in equity or convertible debt during the interim period.
- Escalation Shares: Former Calidi stockholders may receive up to 18,000,000 additional shares of FLAG Class A Common Stock over a 5-year period if the stock price reaches specific thresholds ($12.00, $14.00, $16.00, and $18.00).
- Non-Redeeming Continuation Shares: Up to 2,000,000 shares are available to FLAG public stockholders who do not redeem their shares, contingent on achieving the same price targets.
Material Changes and Transaction Structure
The primary material change is the execution of the Merger Agreement, transitioning Calidi from a private entity to a public company via a SPAC merger. Key structural elements include:
- Consideration: Calidi shareholders will receive FLAG Class A Common Stock and contingent Escalation Shares.
- Pre-Closing Milestones: If Calidi secures a revenue-generating collaboration or out-license contract before closing, the merger consideration will increase by the amount of up-front cash payments received.
- Stockholder Approvals: The transaction requires approval from both FLAG and Calidi stockholders.
- Redemption Rights: FLAG public stockholders have the right to redeem their shares for a pro rata portion of the trust account.
Guidance, Outlook, Risks, and Contingencies
Outlook and Conditions: The transaction is expected to close after stockholder approvals and satisfaction of customary conditions, including regulatory clearance (Hart-Scott-Rodino) and the effectiveness of the registration statement. The "Outside Date" for termination if conditions are not met is September 14, 2023.
Risks and Contingencies:
- Financing Risk: Failure to secure the required PIPE investment or meet the $15,000,000 minimum cash condition could prevent closing.
- Redemption Risk: High levels of shareholder redemptions could jeopardize the minimum cash requirement.
- Regulatory and Legal: Risks include antitrust reviews, changes in laws, and potential litigation.
- Operational Disruption: The announcement and consummation of the merger may disrupt Calidi's current plans and operations.
- Market Conditions: Risks related to the pharmaceutical industry, global conflicts (e.g., Ukraine), and the impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the final net debt calculation at closing to determine the exact equity consideration.
- Monitor the status of the PIPE investment and whether the $40,000,000 target is met.
- Review the definitive proxy statement for the redemption rate of FLAG stockholders to assess if the $15,000,000 minimum cash condition is satisfied.
- Confirm the stockholder approval results for both FLAG and Calidi.
- Check for any Pre-Closing Milestone Contracts signed by Calidi that would increase the merger consideration.
- Review the Escalation Share terms and the likelihood of achieving the $12.00 to $18.00 price targets over the 5-year period.